Search filters

List of works by Javier Cortes

"New" metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy

scientific article

18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial.

scientific article published in September 2016

A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM).

scientific article published on 16 November 2016

A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies

scientific article

A mouse model uncovers LKB1 as an UVB-induced DNA damage sensor mediating CDKN1A (p21WAF1/CIP1) degradation

scientific article

A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial.

scientific article

A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer

scientific article

A roadmap for accelerated drug approval in breast cancer?

scientific article published on 09 August 2012

ALDH1A3 is epigenetically regulated during melanocyte transformation and is a target for melanoma treatment

scientific article published on 05 June 2017

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

scientific article published on 20 September 2020

Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel

scientific article published in November 2013

Acute lung injury associated with docetaxel and bevacizumab.

scientific article published on 21 September 2007

Adjuvant bevacizumab: positive data from a negative trial

scientific article

Advances in first-line treatment for patients with HER-2+ metastatic breast cancer

scientific article

Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis

scientific article published on 04 October 2011

Association of Pathological Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-analysis

scientific article published on 14 September 2020

Bevacizumab in advanced breast cancer: a new model for the assessment of activity in non-first-line treatment regimens.

scientific article published in October 2013

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, rando

scientific article published on 28 September 2014

Beyond taxanes: the next generation of microtubule-targeting agents

scientific article

Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.

scientific article published on 20 October 2014

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer.

scientific article published on 19 February 2013

Breast cancer and HSP90 inhibitors: is there a role beyond the HER2-positive subtype?

scientific article published on 5 May 2012

Breast-Conservative Surgery Followed by Radiofrequency Ablation of Margins Decreases the Need for a Second Surgical Procedure for Close or Positive Margins

scientific article published on 21 February 2014

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

scientific article

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

scientific article published on 09 July 2014

Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study

scientific article published on 8 March 2013

Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma.

scientific article

Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases

scientific article published on 29 March 2016

Changes in breast cancer reports after pathology second opinion.

scientific article published on 02 April 2014

Circulating tumour cells in early breast cancer

Clinical, Pathological, and Molecular Features of Breast Carcinoma Cutaneous Metastasis

scientific article published in 2021

Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study.

scientific article published in January 2002

Complete Pathological Remission in a Patient with Hormone-Receptor Positive and c-erbB-2 Expression-Negative Breast Cancer Treated with FAC Chemotherapy during Pregnancy ⬇️

scientific article published on July 1, 2010

Contribution of ADAMTS1 as a tumor suppressor gene in human breast carcinoma. Linking its tumor inhibitory properties to its proteolytic activity on nidogen-1 and nidogen-2.

scientific article published on 13 June 2013

Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain ⬇️

scientific article published on October 1, 2010

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients

scientific article

Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004.

scientific article published on 12 February 2013

Different Prognostic Implications of Residual Disease After Neoadjuvant Treatment: Impact of Ki 67 and Site of Response.

scientific article

Do we need biomarkers to predict the benefit of adding adjuvant taxanes for treatment of breast cancer?

scientific article published on 26 January 2012

Docetaxel combined with targeted therapies in metastatic breast cancer

scientific article published on 27 August 2011

Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer

scientific article published in September 2012

ERRATUM: Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity

scientific article published on 11 February 2015

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer

scientific article

Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.

scientific article

Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts.

scientific article published on 14 June 2016

Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies

scientific article

Enhancing global access to cancer medicines

scientific article published on 18 February 2020

Epidermal growth factor receptor pathway inhibitors.

scientific article

Eribulin Mesylate: A Promising New Antineoplastic Agent for Locally Advanced or Metastatic Breast Cancer ⬇️

scientific article published on March 7, 2011

Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer ⬇️

scientific article published on November 14, 2011

Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer

scientific article published on 08 May 2011

Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer

scientific article published on 28 March 2014

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

scientific article published on 2 March 2011

Erratum to: 'Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized con

scientific article published on 3 February 2016

Erratum to: Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies

scientific article published in January 2015

Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing

scientific article published on 31 October 2013

Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.

scientific article published on 15 October 2015

Etirinotecan pegol for the treatment of breast cancer

scientific article published on 16 February 2016

Expert perspectives on biosimilar monoclonal antibodies in breast cancer

scientific article

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

scientific article published on April 2007

Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer.

scientific article

First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients.

scientific article

First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.

scientific article published on 13 February 2012

Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer.

scientific article

Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer

scientific article published on 22 July 2016

Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial).

scientific article published on 25 November 2009

Gene expression-based classifications of fibroadenomas and phyllodes tumours of the breast

scientific article published on 31 January 2015

Genetic evolution of nevus of Ota reveals clonal heterogeneity acquiring BAP1 and TP53 mutations.

scientific article

Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors

scientific article

Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity

scientific article

Genomic profile of breast cancer: cost-effectiveness analysis from the Spanish National Healthcare System perspective.

scientific article published on 12 September 2014

HER2 and hormone receptor-positive breast cancer--blocking the right target

scientific article published on 14 December 2010

HER2 testing: current status and future directions.

scientific article published on 11 September 2013

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.

scientific article

HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer

scientific article

Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial ⬇️

scientific article

Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial ⬇️

scientific article

Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer

scientific article published on 17 July 2013

Hepatic Resection for Liver Metastases as Part of the “Oncosurgical” Treatment of Metastatic Breast Cancer

scientific article published on 01 August 2008

High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.

scientific article published on 2 December 2014

High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy.

scientific article published on 15 September 2015

How to treat hormone receptor-positive, human epidermal growth factor receptor 2-amplified breast cancer

scientific article published on 28 September 2009

Implication of breast cancer phenotype for patients with leptomeningeal carcinomatosis

scientific article

In response: Genomic profile of breast cancer

scientific article published on 22 March 2015

Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab

scientific article published on 05 January 2017

Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA.

scientific article

Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy

scientific article published on 25 February 2021

Influencing cancer treatment

scientific article

Intensive Loading Dose of Trastuzumab Achieves Higher-Than-Steady–State Serum Concentrations and Is Well Tolerated

scientific article published on 21 December 2009

Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.

scientific article

Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study

scientific article

Is the Proportion of Patients Diagnosed with Synchronous Stage IV Breast Cancer Who Survive More than Two Years Increasing over Time?

scientific article published in April 2015

Javier Cortés, MD, on the CLEOPATRA Trial

scientific article

Lkb1 loss promotes tumor progression of BRAF(V600E)-induced lung adenomas

scientific article

Lucitanib for the Treatment of HR+/HER2- Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study

scientific article published on 16 October 2019

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer.

scientific article published on 22 May 2017

Management of the axilla in early breast cancer patients in the genomic era.

scientific article

Methylthioadenosine (MTA) inhibits melanoma cell proliferation and in vivo tumor growth

scientific article

MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients

scientific article published on 7 October 2015

Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer

scientific article

Molecular pathways: targeting hsp90--who benefits and who does not.

scientific article published on 20 June 2012

Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.

scientific article published on December 2012

Multidisciplinary approach to breast cancer diagnosed during pregnancy: Maternal and neonatal outcomes

scientific article published on 30 October 2012

Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile.

scientific article published on 17 August 2015

Neoadjuvant breast cancer treatment as a sensitive setting for trastuzumab biosimilar development and extrapolation.

scientific article published on January 2015

New approach to cancer therapy based on a molecularly defined cancer classification.

scientific article

New approaches in angiogenic targeting for colorectal cancer.

scientific article

Nonpegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study

scientific article published on 01 January 2009

Nontaxane microtubule dynamics inhibitors

scientific article published on March 1, 2011

Novel treatment options in the management of metastatic breast cancer.

scientific article published on May 2011

Outcome of patients following hepatic resection for metastatic cutaneous and ocular melanoma

scientific article published in March 2011

PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition

scientific article published on 22 August 2012

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer

scientific article published on April 2015

POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients

scientific article published on 22 August 2019

Paclitaxel, cisplatin, and vinorelbine combination chemotherapy in metastatic non-small-cell lung cancer.

scientific article

Palbociclib and trastuzumab in HER2-positive advanced breast cancer: Results from the phase II SOLTI-1303 PATRICIA trial

scientific article published on 16 September 2020

Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies

scientific article published on 15 June 2015

Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.

scientific article

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

scientific article

Phase 1b Dose Escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women With HR+, HER2- Advanced Breast Cancer

scientific article published on 30 September 2020

Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene.

scientific article

Phase I dose-escalation study of vinflunine hard capsules administered twice a day for 2 consecutive days every week in patients with advanced/metastatic solid tumors

scientific article published on 01 March 2012

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine

scientific article published on 02 August 2010

Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy

scientific article published on 10 February 2017

Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial

scientific article

Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane ⬇️

scientific article published on 20 January 2015

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

scientific article

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.

scientific article published on 8 January 2014

Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer

scientific article

Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors.

scientific article published on 14 August 2014

Potential clinical applications of halichondrins in breast cancer and other neoplasms.

scientific article published on 08 February 2012

Pregnancy after treatment of breast cancer in young women does not adversely affect the prognosis.

scientific article published on 21 October 2011

Preoperative chemoradiation with oral tegafur within a multidisciplinary therapeutic approach in patients with T3-4 rectal cancer

scientific article published in April 2005

Prognostic and predictive factors and genetic analysis of early breast cancer.

scientific article published on October 2009

Prognostic factors for disease-free survival in patients with T3-4 or N+ rectal cancer treated with preoperative chemoradiation therapy, surgery, and intraoperative irradiation

scientific article published on 6 January 2006

Progress against solid tumors in danger: the metastatic breast cancer example

scientific article published on 27 August 2012

Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.

scientific article published on 13 June 2017

Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer

scientific article published on 09 October 2019

Rationale for targeting fibroblast growth factor receptor signaling in breast cancer

scientific article

Re: Time to Adjuvant Chemotherapy for Breast Cancer in National Comprehensive Cancer Network Institutions

scientific article published on 11 November 2013

Recognizing the place of trials with treatment of physician's choice as the control arm.

scientific article published on 2 March 2015

Reply to A. Ocana et al.

scientific article published in March 2013

Research needs in breast cancer.

scientific article published on 9 November 2016

Risk of Venous Thromboembolism With Bevacizumab in Cancer Patients

scientific article published in The Journal of the American Medical Association

Role of total tumour load of sentinel lymph node on survival in early breast cancer patients.

scientific article

Role of von Willebrand factor levels in the prognosis of stage IV colorectal cancer: do we have enough evidence?

scientific article published on October 2005

Réponse de D. Torrejon, J. Cortes, D. Serpico, S. Di Cosimo à l’article de F. Vasseur et al. : KI67 chez les patientes jeunes présentant un cancer du sein. Gynecol Obstet Fertil 2013; 41(1):16-9

scientific article published on 04 June 2013

Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.

scientific article published on 6 October 2014

Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial ⬇️

scientific article published on 08 July 2016

Safety of bevacizumab in metastatic breast cancer patients undergoing surgery.

scientific article published on 22 December 2011

Small-Cell Cancer of the Breast: What Is the Optimal Treatment? A Report and Review of Outcomes ⬇️

scientific article published on April 20, 2012

Sub-centimeter HER2-Positive Breast Cancer: How Small Is Too Small to Treat?

scientific article published on 06 July 2015

Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer ⬇️

scientific article published on 28 June 2016

Survival of women with inflammatory breast cancer: a large population-based study

scientific article published on 24 March 2014

Tailoring the dosing schedule of nab-paclitaxel in metastatic breast cancer according to patient and disease characteristics: Recommendations from a panel of experts

scientific article published on 28 October 2015

The AURORA pilot study for molecular screening of patients with advanced breast cancer-a study of the breast international group

scientific article

The beautiful history of pertuzumab.

scientific article

The effect of biology in the treatment of small breast tumors

scientific article published in January 2013

The expanding role of pertuzumab in the treatment of HER2-positive breast cancer

scientific article published on 21 May 2015

The intra-tumor heterogeneity of cell signaling factors in breast cancer: p4E-BP1 and peIF4E are diffusely expressed and are real potential targets.

scientific article

The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers

scientific article published on 07 June 2021

The use of bevacizumab among women with metastatic breast cancer: a survey on clinical practice and the ongoing controversy

scientific article published on 5 October 2011

Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors

scientific article published on 09 August 2011

mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions.

scientific article published on 02 May 2012

p95HER2-T cell bispecific antibody for breast cancer treatment

scientific article published on 01 October 2018

Paulina is supported by:

About Paulina

Help